RxDoctor Payments Data

Twana Jaff, MD

Internal Medicine · Martinsville, VANPI 1912130584

Payments from drug & device makers

$678in general payments, 2019–2025

Across 39 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$191
  • Amgen$142
  • Medtronic$56
  • Vanda Pharmaceuticals Inc.$53
  • E.r. Squibb & Sons, L.L.C.$35
  • Astellas Pharma US Inc$34
  • plus $166 from 8 others
$113in research payments, 2019–2025

Across 3 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk$38
  • AstraZeneca$38
  • GSK$38

What the payments were for

  • Food & beverage$678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$678 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$15,084
Medicare patients
87
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$33,001
MounjaroTirzepatide17$19,813
JardianceEmpagliflozin12$18,169
XareltoRivaroxaban18$17,881
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,254
Tresiba Flextouch U-100Insulin Degludec14$12,340
Atorvastatin Calcium160$1,854
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,647
Gabapentin44$1,461
Albuterol Sulfate HfaAlbuterol Sulfate30$1,167
Pantoprazole Sodium74$879
Pravastatin Sodium48$875
Levothyroxine Sodium117$813
Omeprazole40$720
Rosuvastatin Calcium45$687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$191$33,00127 claims
GSKTrelegy Ellipta$30$14,25415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →